Avidity Biosciences Inc
RNAM
Ранг среди акций
#2081
Avidity Biosciences, Inc. is at the forefront of developing a novel class of... Avidity Biosciences, Inc. is at the forefront of developing a novel class of oligonucleotide-based therapies, known as Antibody Oligonucleotide Conjugates (AOCs). Utilizing its proprietary AOC platform, the company engineers treatments that strategically merge the targeted delivery capabilities of monoclonal antibodies with the precise action of oligonucleotide-based therapeutics. This innovative method aims to reach cell and tissue types previously inaccessible to treatment, thereby more effectively addressing the fundamental genetic causes of various diseases. The company was established on November 13, 2012, by Troy E. Wilson, Kent Hawryluk, Mark E. Davis, and Francis Patrick McCormick, and its main office is located in San Diego, California.
Цена акции
$71.34
Последняя синхронизация: 2026-03-03
Рыночная капитализация
$9.84B
Изменение (1 день)
0.00%
Изменение (1 год)
-
Страна
US
Торговля Avidity Biosciences Inc (RNAM)
Категория
Healthcare
Коэффициент P/S для Avidity Biosciences Inc (RNAM)
Коэффициент P/S на 2026 TTM: 0
Согласно последним финансовым отчетам и цене акций Avidity Biosciences Inc, текущий коэффициент P/S (TTM) составляет 0. В конце 2026 он составлял 0.
История P/S для Avidity Biosciences Inc с 2018 по 2026
Коэффициент P/S в конце каждого года
| Год | P/S | Изменить |
|---|---|---|
| 2025 | 533.36 | -28.29% |
| 2024 | 743.81 | 34.08% |
| 2023 | 554.77 | 35.05% |
| 2022 | 410.78 | 27.30% |
| 2021 | 322.68 | 39.17% |
| 2020 | 231.86 | -80.28% |
| 2019 | 1.18K | -83.65% |
| 2018 | 7.19K | 0.00% |
Коэффициент P/S для аналогичных компаний или конкурентов
| Компания | P/S | Разница P/S | Страна |
|---|---|---|---|
| 10.02 | - |
US
|
|
| 40.55 | - |
US
|
|
| 4.19 | - |
AU
|
|
| 10.44 | - |
NL
|
|
| 4.52 | - |
BE
|
